Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases

Current Opinion in Rheumatology

Volumn 14, Issue 3, 2002, Pages 204-211

  Criscione, Lisa G ^a   St Clair, E William ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; D2E7; ETANERCEPT; IMMUNOGLOBULIN FRAGMENT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT DISEASE; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL TRIAL; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOPROLIFERATIVE DISEASE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TUBERCULOSIS; WEGENER GRANULOMATOSIS;

ANTIRHEUMATIC AGENTS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RHEUMATIC DISEASES; SAFETY; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036231929     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200205000-00002     Document Type: Review

References (77)

1. Anti-TNFα therapy of rheumatoid arthritis: What have we learned?
2. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis
3. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
4. Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
5. Infliximab (chimeric anti-tumor necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial
6. Infliximab and methotrexate in the treatment of rheumatoid arthritis
7. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
8. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
9. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
10. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
11. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
12. Preliminary results of early clinical trials with the fully human anti-TNFα monoclonal antibody D2E7
13. Update on D2E7: A fully human anti-tumor necrosis factor α monoclonal antibody
14. The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2ET) in patients with active RA on methotrexate (MTX)
15. Treatment of rheumatoid arthritis with PEGylated recombinant human soluble tumor necrosis factor receptor type I: A clinical update
16. Efficacy of a novel PEGylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis
17. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis downregulates synovial tumor necrosis factor alpha synthesis
18. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor α blockade in patients with rheumatoid arthritis
19. Pathogenesis of rheumatoid arthritis: The role of synoviocytes
20. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis
21. Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis
22. Severe inflammatory arthritis and lymphadenopathy in the absence of TNF
23. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis
24. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis
25. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
26. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor
27. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients
28. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis
29. 5 integrin expression by osteoclast precursors in vitro and in vivo
30. Inhibition of osteoblast differentiation by tumor necrosis factor-α
31. Tumor necrosis factor-α and interleukin-1β increase the Fas-mediated apoptosis of human osteoblasts
32. Clinical, histologic, and immunophenotypic characteristics of injection site reactions associated with etanercept
33. Tuberculosis associated with infliximab, a tumor necrosis factor a-neutralizing agent
34. Correction of defective host response to Mycobacterium bovis BCG infection in TNF-deficient mice by bone marrow transplantation
35. Tuberculosis reports with etanercept (Enbrel) therapy
36. Updated consensus statement on tumor necrosis factor blocking agents for the treatment of RA and other rheumatic diseases
37. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: By what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?
38. Onset of multiple sclerosis associated with anti-TNF therapy
39. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: Findings in open-label and randomized placebo-controlled trials
40. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
41. Etanercept in children with polyarticular juvenile rheumatoid arthritis
42. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: A pilot study
43. Clinical response to etanercept in polyarticular juvenile rheumatoid arthritis
44. Elevated tumor necrosis factor-alpha biologic activity in psoriatic skin lesions
45. Patterns of cytokine production in psoriatic synovium
46. Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis
47. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis
48. From wheels to feet: A dramatic response of severe chronic psoriatic arthritis to etanercept
49. Treatment of psoriatic arthritis with antitumor necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate
50. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondyloarthropathy: Histologic findings in 8 patients from an open-label pilot study
51. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study
52. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
53. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®): Results of a phase 3 multicenter clinical trial
54. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
55. Transgenic mice expressing a truncated Peromyscus leucopus TNF-α gene manifest an arthritis resembling ankylosing spondylitis
56. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
57. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade with infliximab on articular symptoms
58. TNF-alpha blockade with infliximab in patients with active spondyloarthropathy: Follow up of one year maintenance regimen
59. A randomized, double-blind, placebo-controlled trial of etanercept (Enbrel) in the treatment of ankylosing spondylitis
60. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (infliximab) versus placebo in active spondyloarthropathy
61. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumor necrosis factor α
62. Quality of life improvement in patients with severe ankylosing spondylitis upon treatment with the anti-TNFα antibody infliximab in a placebo controlled multicenter trial
63. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study
64. Remission of Behçet's syndrome with tumor necrosis factor alpha blocking therapy
65. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: A case report
66. Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab
67. Effect of infliximab on sight-threatening panuveitis in Behçet's disease
68. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease
69. Etanercept therapy in children with treatment-resistant uveitis
70. Infliximab in the treatment of adult Still's disease refractory to conventional therapy
71. Elevated serum interleukin-6, interferon-γ and tumor necrosis factor-α levels in patients with adult Still's disease
72. Opsonization of apoptotic neutrophils by anti-neutrophil cytoplasmic antibodies (ANCA) leads to enhanced uptake by macrophages and increased release of tumor necrosis factor alpha
73. Cytokine profiles in Wegener's granulomatosis: Predominance of type 1 (TH1) in the granulomatous inflammation
74. In situ production of TNF-α, IL-1β, and IL-2R in ANCA-positive glomerulonephritis
75. Enhanced expression of the tumor necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis
76. Etanercept combined with conventional treatment in Wegener's granulomatosis